Abstract
Objective
Survivorship care plans (SCPs) are recommended to promote appropriate follow-up care, but implementation has been limited. We conducted a randomized controlled trial comparing three SCP delivery models in two health systems. We utilize mixed methods to compare the feasibility and participants’ perceived value of the three models.
Methods
Patients completing treatment for stage I–III breast, prostate, or colorectal cancer from one urban-academic and one rural community cancer center were randomized to (1) mailed SCP, (2) SCP delivered during an in-person survivorship visit, or (3) SCP delivered during an in-person survivorship visit plus 6-month follow-up. Clinics had flexibility in intervention implementation. Quantitative data summarize intervention fidelity and protocol deviations. Qualitative interview data provide patients’ perspectives on feasibility and intervention value.
Results
Of 475 eligible participants approached, 378 (79%) were randomized. Of 345 SCPs delivered, 265 (76.8%) were by protocol. Protocol deviations were more common at the urban-academic center. In post-study qualitative interviews, participants recalled little about the SCP document or visit(s). SCPs were valued for information and care coordination, although their static nature was limiting, and sometimes SCP information differed from that provided elsewhere. Visits were opportunities for care and reassurance, but time and distance to the clinic were barriers.
Conclusions
SCP provision was challenging. Patients were interested in SCP, but not necessarily additional survivorship visits, particularly at the urban-academic hospital.
Implications for Cancer Survivors
These findings suggest that patients value careful consideration of health care needs during the transition out of treatment; SCP documents are one element of this. For many patients, models without additional visits and dynamic SCPs may be preferred.
Similar content being viewed by others
Availability of data and material (data transparency)
De-identified data are available by request
Code availability
N/A
References
Rowland JH, Bellizzi KM. Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol. 2014;32(24):2662 2668.
Leach CR, Weaver KE, Aziz NM, Alfano CM, Bellizzi KM, Kent EE, ... & Rowland JH. The complex health profile of long-term cancer survivors: prevalence and predictors of comorbid conditions. J Cancer Surviv2015;9(2):239-251.
Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidem Biomar. 2016;25(7):1029–36.
Institute of Medicine and National Research Council. From cancer patient to cancer survivor: lost in transition. Washington: The National Academies Press; 2006. https://doi.org/10.17226/11468. Accessed March 24, 2021
Keesing S, McNamara B, Rosenwax L. Cancer survivors’ experiences of using survivorship care plans: a systematic review of qualitative studies. J Cancer Surviv. 2015;9(2):260–8.
Blaes AH, Adamson PC, Foxhall L, Bhatia S. Survivorship care plans and the commission on cancer standards: the increasing need for better strategies to improve the outcome for survivors of cancer. J Oncol Pract. 2020;16(8):447–50.
Kenzik KM, Kvale EA, Rocque GB, Demark-Wahnefried W, Martin MY, Jackson BE, et al. Treatment summaries and follow-up care instructions for cancer survivors: improving survivor self-efficacy and health care utilization. Oncologist. 2016;21(7):817 824.
Grunfeld E, Julian JA, Pond G, Maunsell E, Coyle D, Folkes A, et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol. 2011;29(36):4755–62.
Brennan ME, Gormally JF, Butow P, Boyle FM, Spillane AJ. Survivorship care plans in cancer: a systematic review of care plan outcomes. Brit J Cancer. 2014;111(10):1899–908.
Birken SA, Raskin S, Zhang Y, Lane G, Zizzi A, Pratt-Chapman M. Survivorship care plan implementation in US cancer programs: a national survey of cancer care providers. J Cancer Educ. 2019;34(3):614–22.
Smith T, Snyder C. Is it time for (Survivorship Care) Plan B? J Clin Oncol. 2011;2(36):4740–1.
Birken SA, Urquhart R, Munoz-Plaza C, Zizzi AR, Haines E, Stover A, ... & Hahn EE. Survivorship care plans: are randomized controlled trials assessing outcomes that are relevant to stakeholders? J Cancer Surviv 2018;12(4): 495-508.
Choi Y, Smith KC, Shukla A, et al. Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines? Breast Cancer Res Treat. 2020;179:415–24.
Choi Y, Smith KC, Shukla A, Tran P, Peairs K, De Marco T, et al. What are survivorship care plans failing to tell men after prostate cancer treatment? Prostate. 2021. https://doi.org/10.1002/pros.24116.
Birken SA, Clary AS, Bernstein S, Bolton J, Tardif-Douglin M, Mayer DK, ... & Jacobs SR. Strategies for successful survivorship care plan implementation: results from a qualitative study. J Oncol Pract. 2018; 14(8):e462-e483
Stricker CT, O’Brien M. Implementing the Commission on Cancer’s standards for survivorship care. Clin J Oncol Nurs. 2014;18(Feb2014supplement):15–22.
Isaacson MJ, Hulme PA, Cowan J, Kerkvliet J. Cancer survivorship care plans: processes, effective strategies, and challenges in a Northern Plains rural state. Public Health Nurs. 2018;35(4):91–298.
Keats MR, Shea K, Parker L, Stewart SA, Flanders A, Bernstein M. After childhood cancer: a qualitative study of family physician, parent/guardian, and survivor information needs and perspectives on long-term follow-up and survivorship care plans. J Cancer Educ. 2019;34(4):638–46.
Funding
This study was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (IHS-1409-22534). The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins receives funding from the National Cancer Institute (P30CA006973).
Author information
Authors and Affiliations
Contributions
Conceptualization: KCS, CFS
Data curation: JDS, NM, SW, SH
Formal Analysis: KCS, SH
Funding acquisition: KCS, AW, PT, ET, JB, NA, KSP, ES-H, CFS
Investigation: KCS, SH, CFS
Methodology: KCS, SH, CFS
Project administration: CFS, KCS
Resources: not applicable
Software: not applicable
Supervision: CFS, KCS
Validation: SW, SH
Visualization: not applicable
Writing—original draft: KCS
Writing—review and editing: all authors
Corresponding author
Ethics declarations
Ethical review
This study was reviewed and approved by the Johns Hopkins School of Medicine IRB (#110605).
Consent
All data are from individuals who provided written consent to participate.
Consent for publication
N/A
Conflict of Interest
Dr. Nita Ahuja has licensed methylation biomarkers to Cepheid (PATENT # 10167513) and is a member of the Van Andel Institute-Stand Up To Cancer Research Dream Team. Dr. Ahuja is a member of the Scientific Advisory Council to the No Stomach for Cancer Foundation and the Yale New Haven Hospital Board of Trustees.
Dr. Kimberly S. Peairs received research grant support from the Merck Foundation.
Dr. Claire Snyder currently receives research support through the institution from Pfizer and Genentech and previously received royalties from UptoDate for section authorship related to survivorship.
Dr. Phuoc T. Tran reports grants from Astellas Pharm, Bayer Healthcare, and RefleXion Medical; and advisory board/consulting for Noxopharm, Janssen- Taris Biomedical, AstraZeneca, and Myovant outside the submitted work. In addition, Dr. Tran has a patent 9114158—Compounds and Methods of Use in Ablative Radiotherapy licensed to Natsar Pharm.
The remaining authors declare that they have no conflict of interests.
Disclaimer
The statements in this publication are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or the Methodology Committee.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Smith, K.C., White, S., DeSanto, J. et al. Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial. J Cancer Surviv 16, 791–800 (2022). https://doi.org/10.1007/s11764-021-01073-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11764-021-01073-z